Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 Jul 22;23(1):398.
doi: 10.1186/s12916-025-04200-0.

Trajectory of the body weight after drug discontinuation in the treatment of anti-obesity medications

Han Wu #  1 , Wenjia Yang #  1 , Tong Guo  1 , Xiaoling Cai  2 , Linong Ji  3
Affiliations
Meta-Analysis

Trajectory of the body weight after drug discontinuation in the treatment of anti-obesity medications

Han Wu et al. BMC Med. .

Abstract

Background: Globally, obesity has emerged as a significant public health concern, imposing detrimental impacts on human health. The purpose of our study was to explore the long-term effects of anti-obesity medications (AOMs) on body weight and to draw the trajectory of weight change after discontinuation of AOMs.

Methods: PubMed, Medline, Embase, the Cochrane Center Register of Controlled Trials for Studies, and Clinicaltrials.gov were searched from the inception to March 2024. Randomized controlled trials of AOMs conducted in population for at least 4 weeks and followed for 4 or more weeks after discontinuation were included. Weight change during treatment and after drug discontinuation was also reported. Random-effect model and meta-regression analysis were accordingly used.

Results: At week 4 after discontinuation, compared with the control group, AOM treatment still had weight loss effect (WMD = - 0.32 kg, 95% CI - 3.60-2.97, P = 0.85, I2 = 83%). At 8 weeks after drug discontinuation, AOMs were associated with significant weight regain compared with the control group (WMD = 1.50 kg, 95% CI 1.32-1.68, P < 0.0001, I2 = 0.0%). The weight regain trend remained at 12 and 20 weeks (WMD = 1.76 kg, 95% CI 1.29-2.24, P < 0.0001, I2 = 72.0%; WMD = 2.50 kg, 95% CI 2.27-2.73, P < 0.0001, I2 = 0.0%). Among the different subgroups of AOMs, significant weight regain after 12 weeks of drug discontinuation was observed only in studies with glucagon-like peptide 1 receptor agonist (GLP-1 RA) related drugs. In addition, studies in which weight loss was greater during treatment than in the control group and studies in which lifestyle interventions were continued observed significant weight gain after drug discontinuation.

Conclusion: Significant weight regain occurred 8 weeks after discontinuation of AOMs and was sustained through 20 weeks. Different weight regain was observed in subjects with different characteristics. Studies with longer follow-up duration are required to further investigate the potential factors associated with weight change after discontinuation of treatment.

Keywords: Anti-obesity medication; Meta-analysis; Treatment discontinuation; Weight change trajectory.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Weight change at specific time point after treatment discontinuation. AOM: anti-obesity medication
Fig. 2
Fig. 2
Weight and BMI regain trajectory after treatment of AOM withdrawal. BMI: body mass index
Fig. 3
Fig. 3
Weight change trajectory of included studies after treatment of AOM withdrawal
Fig. 4
Fig. 4
Weight change in GLP-1 related and non GLP-1 related subgroup after 12 weeks of treatment discontinuation
Fig. 5
Fig. 5
GLP-1: glucagon-like peptide 1
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. World Obesity Federation. World Obesity Atlas. 2024. Available at: https://data.worldobesity.org/publications/?cat=22. Accessed March, 2024.
    1. Ortega FB, Lavie CJ, Blair SN. Obesity and cardiovascular disease. Circ Res. 2016;118(11):1752–70. - PubMed
    1. Abdullah A, Peeters A, de Courten M, Stoelwinder J. The magnitude of association between overweight and obesity and the risk of diabetes: a meta-analysis of prospective cohort studies. Diabetes Res Clin Pract. 2010;89(3):309–19. - PubMed
    1. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625–38. - PubMed
    1. Grover SA, Kaouache M, Rempel P, et al. Years of life lost and healthy life-years lost from diabetes and cardiovascular disease in overweight and obese people: a modelling study. Lancet Diabetes Endocrinol. 2015;3(2):114–22. - PubMed

MeSH terms

Substances

LinkOut - more resources